What is the story about?
Laurus Labs Ltd. reported its results for the September quarter on Thursday, October 23, which were higher than analyst expectations on most parameters.
Revenue for the quarter increased by 35.2% from the same quarter last year to ₹1,653 crore, which is higher than the CNBC-TV18 poll expectation of ₹1,553.1 crore.
Earnings Before Interest, Tax, Depreciation and Amortisation (EBITDA) for the quarter increased by 126% to ₹403 crore. A CNBC-TV18 poll had projected the figure to be ₹368.3 crore.
EBITDA margin for the quarter expanded by more than 1,000 basis points from last year to 24.4%, higher compared to the CNBC-TV18 poll projection of 23.7%. This is the fourth straight quarter that Laurus Labs has reported EBITDA margin in excess of 20%.
Net profit for the period stood at ₹195 crore, while the CNBC-TV18 poll had projected the figure to be ₹147 crore. Laurus Labs had reported a net profit of ₹20 crore in the base quarter.
On Monday, brokerage firm B&K Securities had initiated coverage on Laurus Labs with a "buy" rating and a price target of ₹1,030. The firm said that Laurus Labs is entering a strong growth cycle led by its high-margin CDMO business, which has gradually emerged as the company's key earnings driver.
Shares of Laurus Labs are trading 0.9% higher at ₹932.4. The stock trades close to its record high level of ₹944. Shares of gained 51% so far on a year-to-date basis.
Revenue for the quarter increased by 35.2% from the same quarter last year to ₹1,653 crore, which is higher than the CNBC-TV18 poll expectation of ₹1,553.1 crore.
Earnings Before Interest, Tax, Depreciation and Amortisation (EBITDA) for the quarter increased by 126% to ₹403 crore. A CNBC-TV18 poll had projected the figure to be ₹368.3 crore.
EBITDA margin for the quarter expanded by more than 1,000 basis points from last year to 24.4%, higher compared to the CNBC-TV18 poll projection of 23.7%. This is the fourth straight quarter that Laurus Labs has reported EBITDA margin in excess of 20%.
Net profit for the period stood at ₹195 crore, while the CNBC-TV18 poll had projected the figure to be ₹147 crore. Laurus Labs had reported a net profit of ₹20 crore in the base quarter.
On Monday, brokerage firm B&K Securities had initiated coverage on Laurus Labs with a "buy" rating and a price target of ₹1,030. The firm said that Laurus Labs is entering a strong growth cycle led by its high-margin CDMO business, which has gradually emerged as the company's key earnings driver.
Shares of Laurus Labs are trading 0.9% higher at ₹932.4. The stock trades close to its record high level of ₹944. Shares of gained 51% so far on a year-to-date basis.
Do you find this article useful?

/images/ppid_59c68470-image-176104008964323540.webp)
/images/ppid_59c68470-image-17609350634436018.webp)
/images/ppid_59c68470-image-176103502791236448.webp)
/images/ppid_59c68470-image-176114753103515793.webp)
/images/ppid_59c68470-image-176119502886941900.webp)
/images/ppid_59c68470-image-176120012674681132.webp)
/images/ppid_59c68470-image-176120258247090480.webp)
/images/ppid_59c68470-image-176120752684263474.webp)
/images/ppid_59c68470-image-176120002666494070.webp)
/images/ppid_59c68470-image-176121255840418111.webp)
/images/ppid_59c68470-image-176103257503486935.webp)
/images/ppid_59c68470-image-176093517598795442.webp)